Table 2.
Factors associated with the progression‐free survival of patients with anaplastic lymphoma kinase‐positive lung adenocarcinoma treated with crizotinib
| Characteristic | HR (95% CI) | p value | Adjusted HR (95% CI) | p value |
|---|---|---|---|---|
| Age ≥65 vs <65, years | 0.925 (0.407–2.104) | .852 | ||
| Male vs. female sex | 0.744 (0.397–1.392) | .355 | ||
| Smoker vs. nonsmoker | 1.039 (0.518–2.083) | .914 | ||
| Stage IIIB vs. IV | 2.448 (1.127–5.317) | .024 | 1.625 (0.717–3.682) | .244 |
| ECOG 2–4 vs. 0–1 | 0.729 (0.257–2.068) | .552 | ||
| Line of therapy ≥2nd line vs. 1st line | 0.531 (0.278–1.013) | .055 | ||
| PD‐L1 expression | ||||
| <50% vs. ≥50% | 0.522 (0.250–1.089) | .083 | ||
| 0% vs. ≥1% | 0.421 (0.224–0.793) | .007 | 0.322 (0.160–0.650) | .002 |
| Metastases | ||||
| Brain (positive vs. negative) | 2.404 (1.191–4.854) | .014 | 1.693 (0.725–3.957) | .224 |
| Liver (positive vs. negative) | 1.944 (0.892–4.236) | .095 | 2.197 (0.942–5.125) | |
| Bone (positive vs. negative) | 2.820 (1.479–5.376) | .002 | 2.813 (1.345–5.885) | .006 |
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; PD‐L1, programmed death‐ligand 1; PFS, progression‐free survival.